Wellington Management Group LLP Sells 25,916 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Wellington Management Group LLP trimmed its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 69.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 11,152 shares of the medical equipment provider's stock after selling 25,916 shares during the quarter. Wellington Management Group LLP's holdings in Zimmer Biomet were worth $1,178,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $25,000. Kentucky Trust Co acquired a new stake in Zimmer Biomet in the fourth quarter valued at about $39,000. OFI Invest Asset Management acquired a new position in Zimmer Biomet during the fourth quarter worth about $40,000. SRS Capital Advisors Inc. lifted its holdings in shares of Zimmer Biomet by 146.9% in the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock worth $51,000 after acquiring an additional 285 shares during the last quarter. Finally, Atala Financial Inc acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at approximately $51,000. Institutional investors own 88.89% of the company's stock.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.95% of the stock is currently owned by insiders.

Zimmer Biomet Stock Up 1.0 %

Shares of ZBH stock traded up $0.96 during trading hours on Friday, reaching $97.90. The company had a trading volume of 4,367,870 shares, compared to its average volume of 1,651,530. Zimmer Biomet Holdings, Inc. has a 12 month low of $96.58 and a 12 month high of $123.96. The business has a fifty day simple moving average of $105.92 and a 200-day simple moving average of $106.72. The company has a market cap of $19.37 billion, a price-to-earnings ratio of 22.00, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the company earned $2.20 EPS. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.98%. Zimmer Biomet's payout ratio is 21.57%.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James cut their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Truist Financial reaffirmed a "hold" rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. Finally, Barclays cut their target price on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.